Últimas noticias sobre Addex Therapeutics (NASDAQ:ADXN) Bolsa

Addex Therapeutics

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

The dividend will be paid on March 14, 2025, to all holders of record of the Company's restricted and unrestricted common stock as of February 28, 2025.

News

Dividends

Walker & Dunlop Boosts Dividend By 3% From $0.65 To $0.67 Per Share

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and raises the price target from $8 to $10.

Price Target

Reiteration

Analyst Ratings

HIVE

HC Wainwright & Co. Reiterates Buy on HIVE Digital Technologies, Raises Price Target to $10

Kubota (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KUBTY#OTC">KUBTY</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $0.96 by 2.08 percent. This is a 41.61 percent decrease over earnings of $1.61 per share from the same period last year. The company reported quarterly sales of $4.85 billion which missed the analyst consensus estimate of $4.97 billion by 2.45 percent. This is a 6.06 percent decrease over sales of $5.16 billion the same period last year.

Earnings

Earnings Misses

KUBTY

Kubota Q4 EPS $0.94 Misses $0.96 Estimate, Sales $4.85B Miss $4.97B Estimate

WIIM

Walker & Dunlop shares are trading higher following a Q4 earnings beat.

Wells Fargo analyst Mohit Bansal upgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Equal-Weight to Overweight and raises the price target from $130 to $170.

Upgrades

JAZZ

Wells Fargo Upgrades Jazz Pharmaceuticals to Overweight, Raises Price Target to $170

Guidance

TransUnion Sees FY25 Adj. EPS $3.93-$4.08 vs. $4.46 Est., Revenue $4.333B-$4.393B vs. $4.48B Est.

2025 guidance
Today, the Company introduces 2025 full-year guidance, which includes the estimated impact from recently implemented U.S. tariffs on products from China.
2025 guidance is as follows:
<ul>
<li>Organic revenue growth of 2% to 3% year-over-year, which reflects continued demand for our products and services as well as a measured view of market conditions in China</li>
<li>Adjusted EBIT margin of 16.7% to 16.8%, reflecting an expansion of approximately 40 to 50 basis points versus 2024 Adjusted EBIT margin of 16.3%</li>
<li>Adjusted effective tax rate (ETR) in the range of 22% to 23%</li>
<li>Adjusted EPS in the range of $4.61 to $4.75, representing 3% to 6% growth versus Adjusted EPS&#x2A; of $4.49 for 2024</li>
<li>Free cash flow of at least $1.75 billion</li>
</ul>

Health Care

General

GEHC

GE HealthCare Forecasts 2025 Adjusted EPS Of $4.61-$4.75 Versus Consensus Of $4.66

TransUnion Sees Q1 Adj. EPS $0.96-$0.99 vs. $1.05 Est., Revenue $1.06B-$1.074B vs. $1.096B Est.

Nissan Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) &nbsp;Sees FY2024 GAAP EPS JPY (22.31); &nbsp;Sales JPY 12500B. &nbsp;

NSANY

Nissan Motor Co Sees FY2024 GAAP EPS JPY (22.31);  Sales JPY 12500B.

GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.26 by 15.08 percent. This is a 22.88 percent increase over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $5.32 billion which missed the analyst consensus estimate of $5.33 billion by 0.21 percent. This is a 2.17 percent increase over sales of $5.21 billion the same period last year.

GE HealthCare Techs Q4 2024 Adj EPS $1.45 Beats $1.26 Estimate, Sales $5.32B Miss $5.33B Estimate

Nissan Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) reported quarterly losses of $(0.06) per share. This is a 154.55 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $20.74 billion in sales this quarter. This is a 1.41 percent decrease over sales of $21.04 billion the same period last year.

Nissan Motor Co Q3 2024 GAAP EPS $(0.06) Down From $0.11 YoY, Sales $20.74B Down From $21.04B YoY

Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) reported quarterly losses of $(1.32) per share. This is a 99.17 percent increase over losses of $(158.40) per share from the same period last year. The company reported $4.43 million in sales this quarter. This is a 47.65 percent decrease over sales of $8.46 million the same period last year.

BENF

Beneficient Q3 GAAP EPS $(1.32) Up From $(158.40) YoY, Sales $4.43M Down From $8.46M YoY

Earnings Beats

TransUnion Q4 2024 Adj. EPS $0.97 Beats $0.96 Estimate, Sales $1.037B Beat $1.027B Estimate

Buybacks

Walker & Dunlop Board Authorizes Repurchase Of Up To $75M Of Outstanding Common Stock Over Twelve-month Period

Deere & Company shares are trading lower following Q1 financial results.

TransUnion Board Authorizes Repurchase Up To $500M

Canadian Tire Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CDNAF#OTC">CDNAF</a>) reported quarterly earnings of $2.91 per share. This is a 17.34 percent increase over earnings of $2.48 per share from the same period last year. The company reported quarterly sales of $3.22 billion. This is a 1.26 percent decrease over sales of $3.26 billion the same period last year.

CDNAF

Canadian Tire Corp Q4 Adj EPS $2.91 up from $2.48 in prior year , Sales $3.22B down from $3.264B last year.

UBS analyst Matthew Weston downgrades Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral.

Downgrades

UBS Downgrades Novartis to Neutral

YETI

YETI Expects FY25 Adjusted Sales To Increase 5% - 7%; Adjusted EPS Of $2.90 - $2.95, Est $2.89

2025 Outlook
"As we shared at our Investor Day in December, we laid out a path to grow organic sales 100 – 200 basis points above GDP with margin expansion by intersecting high growth markets and secular trends with our technologies to create platforms that scale," said Jamie Beggs, Senior Vice President and Chief Financial Officer, Avient Corporation. "As we begin 2025, we are poised to execute our strategy to deliver value for our shareholders by prioritizing our portfolio, amplifying innovation, leveraging digital technologies and harnessing the collective strengths of our more than 9,000 global employees."
"Looking ahead, we are projecting first quarter adjusted EPS to be $0.76, which is in-line with the prior year quarter and includes a $0.04 foreign exchange headwind due to the stronger U.S. dollar," added Ms. Beggs. "This translates to 6% adjusted EPS growth, excluding the impact of foreign exchange, and an encouraging start to the year, especially considering the outsized timing of defense orders that benefited the first quarter last year."
"The current macro environment presents several uncertainties related to policy, inflation, foreign exchange and interest rates which provides for a broader set of potential outcomes for the year," Ms. Beggs said. "Our best full year forecast using present information is an adjusted EBITDA range of $540 to $570 million and adjusted EPS range of $2.70 to $2.94. The mid-point of the adjusted EPS range of $2.82 represents 11% growth, excluding the unfavorable impact from foreign exchange of $0.12 for the full year."
Dr. Khandpur added, "Despite the near-term uncertainties in the macro environment, we remain focused on what we can control: staying close to our customers and executing our strategy. Building off our strong performance in 2024, I remain optimistic in our team's ability to achieve the long-term financial targets we shared at Investor Day last December."

AVNT

Avient Exepcts Q1 Adj. EPS Of $0.76 (Inline With Consensus); For 2025 Sees Adj EBITDA range of $540M-$570M And Adj. EPS range of $2.70-$2.94 (Vs. $2.88 Consesnus)

Addex stock rallies 45% on Indivior collaboration update

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report) and keeping the price target at $...

Positive Outlook for Addex Therapeutics: Significant Collaboration Payments and Promising Pipeline Drive Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Addex Therapeutics (ADXN – Research Report) and Avid...

Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)

Shares of Addex Therapeutics ($ADXN) have rallied in the past few days, soaring by 43%, after the company announced the selection of clinical candi...

Clinical Collaboration Ignites Addex Therapeutics (ADXN) Stock Rally

Addex Therapeutics reports H1 results

Addex Therapeutics GAAP EPS of CHF0.08, revenue of CHF0.12M

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report), with a price...

Comments

Addex Therapeutics

Noticias

Últimas noticias sobre Addex Therapeutics (NASDAQ:ADXN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL